Coronary artery disease and depression.

Area of Science:

• Cardiology
• Psychiatry
• Pharmacology

Background:

• Coronary artery disease (CAD) and depression are highly prevalent, significantly reducing patient quality of life and imposing economic burdens.
• Depression is linked to CAD development and poorer outcomes due to factors like poor medication adherence, endothelial dysfunction, and altered heart rate variability.
• Emerging evidence suggests depression is an independent risk factor for cardiac events in both general and established CAD populations, especially post-myocardial infarction.

Purpose of the Study:

• To review the relationship between depression and coronary artery disease (CAD).
• To evaluate the impact of depression treatment on cardiovascular prognosis.
• To discuss pharmacological options for treating depression in patients with comorbid CAD.

Main Methods:

• Literature review of studies investigating the link between depression and CAD.
• Analysis of evidence regarding the effect of depression treatment on cardiovascular outcomes.
• Assessment of antidepressant medication safety and efficacy in CAD patients.

Main Results:

• Depression treatment improves quality of life but has not definitively improved cardiovascular prognosis in CAD patients.
• Selective serotonin reuptake inhibitors (SSRIs) are generally preferred over tricyclic antidepressants for comorbid CAD due to better tolerability and fewer cardiovascular side effects.
• Hypericum perforatum (St. John's wort) may interact dangerously with cardioactive drugs, necessitating caution.

Conclusions:

• Depression is an independent risk factor for cardiac events, underscoring the need for integrated care.
• While depression treatment enhances quality of life, its impact on cardiovascular prognosis remains uncertain, warranting large-scale clinical trials.
• Careful selection of antidepressants, favoring SSRIs and cautioning against St. John's wort interactions, is crucial for managing comorbid depression in CAD patients.